Search results for "Cardiovascular agent"

showing 10 items of 72 documents

Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.

2007

Drug-eluting stents are increasingly used to reduce in-stent restenosis and adverse cardiac events after percutaneous coronary interventions. However, the race for the ideal drug-eluting stent is still on, with special regard to the best stent-coating system and the most effective and less toxic drug. Fludarabine, a nucleoside analog, has both anti-inflammatory and antiproliferative cellular effects. The aim of the present study was to assess the cellular and molecular effects of fludarabine on vascular smooth muscle cell (VSMC) growth in vitro and in vivo and the feasibility and efficacy of a fludarabine-eluting stent. To study the biomolecular effects of fludarabine on VSMC proliferation…

Malemedicine.medical_specialtyVascular smooth muscleTime FactorsPhysiologyMyocytes Smooth MusclePharmacologyProsthesis DesignTransfectionMuscle Smooth VascularRestenosisIn vivoPhysiology (medical)medicineAnimalsCarotid StenosisRNA AntisensePhosphorylationRats WistarAortaCells CulturedCell ProliferationNeointimal hyperplasiaHyperplasiaDose-Response Relationship Drugbusiness.industryCardiovascular AgentsHyperplasiaJanus Kinase 2medicine.diseaseFludarabineSurgeryRatsDisease Models AnimalSTAT1 Transcription FactorCardiovascular agentSTAT proteinFeasibility StudiesStentsRabbitsCardiology and Cardiovascular MedicinebusinessCarotid Artery InjuriesTunica IntimaAngioplasty BalloonVidarabinemedicine.drug
researchProduct

Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions

2015

Background Through contemporary literature, the optimal strategy to manage coronary chronic total occlusions (CTOs) remains under debate. Objectives The aim of the Italian Registry of Chronic Total Occlusions (IRCTO) was to provide data on prevalence, characteristics, and outcome of CTO patients according to the management strategy. Methods The IRCTO is a prospective real world multicentre registry enrolling patients showing at least one CTO. Clinical and angiographic data were collected independently from the therapeutic strategy [optimal medical therapy (MT), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG)]; a comparative 1-year clinical followup was pe…

Malemedicine.medical_specialtymedicine.medical_treatmentLeftCoronary AngiographyVentricular Dysfunction LeftCoronary artery bypass surgeryPercutaneous Coronary InterventionInternal medicineVentricular DysfunctionPrevalenceHumansMedicineProspective StudiesRegistriesMyocardial infarctionCoronary Artery BypassProspective cohort studyCABGAgedbusiness.industryChronic total occlusion † Registry † PCI † CABG † Optimal medical therapyPercutaneous coronary interventionCardiovascular AgentsPCImedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareChronic total occlusionTreatment Outcomemedicine.anatomical_structureCoronary OcclusionItalyCoronary occlusionChronic total occlusion; PCI; CABGChronic DiseaseCardiovascular agentConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessArteryEuropean Heart Journal
researchProduct

Retinal vascular imaging in cardiovascular medicine: New tools for an old examination

2017

The old concept that the eye is the only window through which the body microcirculation can be observed in life easily, safely and repeatedly is part of the cultural baggage of every physician. When Hermann von Helmholtz invented the direct ophthalmoscope in 1850, he opened the door to a non-invasive visualization of human microcirculation in vivo at the retina. Only a few years later, the Scottish ophthalmologist Marcus Gunn documented the close association between retinal changes, and renal and cardiovascular diseases (CVD) in hypertensive patient. In 1939, Keith, Wagener, and Barker showed that the severity of retinal microvascular abnormalities was predictive of mortality in patients wi…

Pathologymedicine.medical_specialtySettore MED/09 - Medicina InternaMEDLINECoronary Artery Disease030204 cardiovascular system & hematologyCardiovascular SystemRetinaCoronary artery disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningmedicineHumansrenal diseases coronary diseaseSettore MED/14 - NefrologiaRetinaVascular imagingSettore MED/30 - Malattie Apparato Visivobusiness.industryCardiovascular AgentsRetinalmedicine.diseasecardiovascular diseasesmedicine.anatomical_structurechemistryretinal imagingHypertensionCardiovascular agentFundus oculiCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryAtherosclerosis
researchProduct

Cardiovascular and Cardioprotective Agents in 2021

2021

Pharmacology2019-20 coronavirus outbreakCardiotonic AgentsCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cardiovascular AgentsPharmacologyCardiovascular SystemCardiovascular DiseasesDrug DiscoveryCardiovascular agentHumansMedicineCardioprotective AgentbusinessCurrent Pharmaceutical Design
researchProduct

Untersuchungen �ber die Einwirkung von verschiedenen Pharmaka auf die Spontanrhythmik des isolierten H�hneramnion

1954

1. Das isolierte Huhneramnion nach Baur eignet sich gut, um Fragen nach der Entstehung der Erregung, deren Weiterleitung und Koordination, dem Angriffspunkt und der Wirkungsweise von Pharmaka zu prufen, da es sich um ein nervenfreies, rhythmische Kontraktionen ausfuhrendes Organ handelt, das praparativ leicht zu handhaben ist. 2. Auf die erregende Wirkung von Acetylcholin, Nicotin und Bariumionen sind d-Tubocurarin, Decamethonium, Atropin, Hexamethonium und Pentamethonium ohne Einflus. 3. Papaverin und Chinin hemmen die genannten erregenden Verbindungen reversibel. 4. Bariumionen fuhren zu Storungen in der Regelmasigkeit der rhythmischen Kontraktionen. Die Deutung dieses Effektes wird in de…

PharmacologyCuraremedicine.anatomical_structureAmnionChemistryCardiovascular agentPharmacology toxicologymedicineGeneral MedicinePharmacologyPhysiological Phenomenonmedicine.drugNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Reduction of myocardial infarct size with sCR1sLex, an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing…

1999

1 This study investigated the effects of soluble complement receptor type 1 (sCR1) or sCR1sLex, agents which function as a complement inhibitor or as a combined complement inhibitor and selectin adhesion molecule antagonist, respectively, on the infarct size and cardiac troponin T (cTnT) release caused by regional myocardial ischaemia and reperfusion in the rat. 2 Eighty-two, male Wistar rats were subjected to 30 min occlusion of the left anterior descending coronary artery (LAD) followed by 2 h of reperfusion. Haemodynamic parameters were continuously recorded and at the end of the experiments infarct size (with p-nitro-blue tetrazolium) and cTnT release were determined. 3 Infusion of sCR1…

Pharmacologymedicine.medical_specialtyTroponin Tbusiness.industryAntagonistmedicine.diseaseComplement systemComplement inhibitorEndocrinologyComplement Receptor Type 1Troponin complexInternal medicineCardiovascular agentImmunologymedicineMyocardial infarctionbusinessBritish Journal of Pharmacology
researchProduct

Psychopharmacological Drugs as Represented in the Press: Results of Systematic Analysis of Newspapers and Popular Magazines

1996

The representation of mental diseases and psychopharmacological drugs in the media, especially in the press, is thought to be of great impact on people's opinions on the subject. During the course of one year, all articles about psychopharmacological drugs and cardiac drugs published in nineteen German newspapers were collected. All statements, together with related aspects, reasons for prescription, individual details of the patient, effects and side-effects, were registered and classified according to a key. The results show that, in contrast to 13% of the articles about cardiac drugs, half of the reports about psychopharmacological drugs deal primarily with the problems of side-effects a…

Psychotropic Drugsmedicine.medical_specialtybusiness.industryMEDLINENewspapers as TopicCardiovascular AgentsContext (language use)General MedicinePublic opinionNewspaperPsychiatry and Mental healthContent analysisGermanyPublic OpinionmedicinePharmacology (medical)Mass MediaMedical prescriptionbusinessPsychologyNewspapers as TopicPsychiatryMass mediaPharmacopsychiatry
researchProduct

Peripheral artery disease: potential role of ACE-inhibitor therapy

2008

Giuseppe Coppola, Giuseppe Romano, Egle Corrado, Rosa Maria Grisanti, Salvatore NovoDepartment of Internal Medicine, Cardiovascular and Nephro-Urological Diseases, Chair of Cardiovascular Disease, University of Palermo, Palermo, ItalyAbstract: Subjects with peripheral arterial disease (PAD) of the lower limbs are at high risk for cardiovascular and cerebrovascular events and the prevalence of coronary artery disease in such patients is elevated. Recent studies have shown that regular use of cardiovascular medications, such as therapeutic and preventive agents for PAD patients, seems to be promising in reducing long-term mortality and morbidity. The angiotensin-converting-enzyme (ACE) system…

Ramiprillcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyPathologyACE inhibitorsEndocrinology Diabetes and MetabolismBradykininAngiotensin-Converting Enzyme InhibitorsReviewDiseaseendothelial dysfunctionCoronary artery diseasechemistry.chemical_compoundperipheral arterial diseaseInternal medicineHumansMedicinePharmacology (medical)Endothelial dysfunctionCell ProliferationSubclinical infectionPeripheral Vascular Diseasesbusiness.industryFibrinolysisPublic Health Environmental and Occupational HealthCardiovascular AgentsPeripheral artery disease ACE-inhibitorintermittent claudicationHematologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolareperipheral arterial disease.Oxidative StressTreatment OutcomeLower ExtremitychemistryCardiovascular Diseaseslcsh:RC666-701ACE-inhibitorsACE inhibitorCardiovascular agentCardiologyEndothelium VascularatherosclerosisCardiology and Cardiovascular Medicinebusinessmedicine.drugVascular Health and Risk Management
researchProduct

Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2)

2011

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a calcium-independent phospholipase A2 that circulates in plasma in association with lipoprotein particles, whereas in atherosclerotic plaques it is co-localized with macrophages. Lp-PLA2 generates two proinflammatory mediators, lysophosphatidylcholine and oxidized nonesterified fatty acids, which play a role in the development of atherosclerotic lesions and formation of a necrotic core, leading to more vulnerable plaques. Epidemiologic studies demonstrate that increased circulating levels of Lp-PLA2 predict an increased risk of myocardial infarction, stroke and cardiovascular mortality. Furthermore, histologic examination of diseased hum…

RiskPathologymedicine.medical_specialtycoronary-artery-diseasecardiovascular-diseasePharmacologyatherosclerotic plaqueProinflammatory cytokinechemistry.chemical_compoundPhospholipase A2cardiovascular diseaseDarapladibOximesDrug DiscoveryHyperlipidemiamedicineHumansMyocardial infarctionPharmacologyClinical Trials as Topicbiologylow-density-lipoproteinLipoprotein-associated phospholipase A2risk-assessmentCardiovascular AgentsAtherosclerosismedicine.diseaselp-pla2heart-diseaselipoproteinsLysophosphatidylcholinechemistryCardiovascular DiseasesinflammationBenzaldehydes1-Alkyl-2-acetylglycerophosphocholine Esterasebiology.proteindarapladibrheumatoid-arthritislipids (amino acids peptides and proteins)atherosclerosisfactor-acetylhydrolase activityAtherosclerosis Cardiovascular disease Darapladib Inflammation Lipoproteins Lp-PLA2.platelet-activating-factorsecondary preventionLipoprotein
researchProduct

Mediterranean Diet and Physical Activity Decrease the Initiation of Cardiovascular Drug Use in High Cardiovascular Risk Individuals: A Cohort Study

2021

Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increas…

StatinMediterranean dietPhysiologymedicine.drug_classClinical Biochemistryphysical activityFibrateantiplatelet drugs030204 cardiovascular system & hematologyPharmacologyLower riskBiochemistryMetabolic equivalentArticlestatinscardiac glycosides03 medical and health sciences0302 clinical medicineMediterranean cookingMediterranean dietCuina mediterràniamedicine030212 general & internal medicinevitamin K epoxide reductase inhibitorsMolecular BiologyCardiac glycosideglucose-lowering drugsbusiness.industrylcsh:RM1-950mediterranean dietCell BiologyVitamin K antagonistPhysical fitnessCardiovascular agentslcsh:Therapeutics. Pharmacologyantihypertensive drugsantianginal drugsfibratesbusinessCohort studymedicine.drugCondició físicaMedicaments cardiovasculars
researchProduct